Pergolide Mesylate Market

The Pergolide Mesylate market is projected to grow at a CAGR of 3.7% from 2025 to 2035, driven by rising cases of Parkinson’s disease and hyperprolactinemia, increasing use of dopamine agonists in neurology and endocrinology, and ongoing clinical interest in ergot-derived compounds. Pergolide Mesylate is an ergot-derived dopamine receptor agonist that exerts its effect by stimulating D1 and D2 dopamine receptors, helping to restore dopaminergic tone in patients with Parkinson’s disease and reducing elevated prolactin levels in endocrine disorders.

Historically used as an adjunct therapy for Parkinson’s disease, Pergolide Mesylate has also shown effectiveness in treating hyperprolactinemia and pituitary tumors due to its prolactin-suppressing effects. Although withdrawn from several markets due to concerns over cardiac valvulopathy associated with long-term use, it remains available in certain regions under controlled conditions, particularly in veterinary medicine for treating equine Cushing’s disease (pituitary pars intermedia dysfunction). Its specialized applications and retained utility in select patient populations continue to support its market presence.

North America maintains a niche market for Pergolide Mesylate, mainly in veterinary applications, supported by high expenditure on equine healthcare and veterinary neurologic treatments. Europe shows limited use, primarily under regulatory oversight for human or veterinary applications. The Asia-Pacific region is expected to experience moderate growth, driven by demand in veterinary markets and limited use in neurological research. Latin America and Africa represent emerging markets where regulatory flexibility and lower-cost therapeutic needs support the continued use of older dopamine agonists.